Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma
Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have limited treatment options, particularly if they are transplantation or chimeric antigen receptor (CAR) T-cell ineligible, and novel therapeutics are needed. An 86-year-old woman with relapsed DLBCL received a novel, firs...
Main Authors: | Randeep Sangha, Neal M. Davies, Afshin Namdar, Michael Chu, Jennifer Spratlin, Erwan Beauchamp, Luc G. Berthiaume, John R. Mackey |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/29/3/158 |
Similar Items
-
GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
by: Mani Ramzi, et al.
Published: (2015-03-01) -
Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond
by: Salvatore Perrone, et al.
Published: (2023-05-01) -
Synchronous Lymphomas: An Uncommon Affair
by: Manohor Vidhya
Published: (2020-08-01) -
Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01) -
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
by: Walter Hanel, et al.
Published: (2023-02-01)